Antihyperglycemic effect of carvacrol in combination with rosiglitazone in high-fat diet-induced type 2 diabetic C57BL/6J mice

Molecular and Cellular Biochemistry

Volumn 385, Issue 1-2, 2014, Pages 23-31

  Ezhumalai, Muthukrishnan ^a   Radhiga, Thangaiyan ^a   Pugalendi, Kodukkur Viswanathan ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Carvacrol; Diabetes mellitus; High fat diet; Insulin resistance; Rosiglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARVACROL; FRUCTOSE BISPHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; INSULIN; ROSIGLITAZONE; UNCLASSIFIED DRUG; WINDIA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; LIPID DIET; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLYCOGEN; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; LIVER; MALE; MICE; MICE, INBRED C57BL; MONOTERPENES; THIAZOLIDINEDIONES;

EID: 84890444690     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1810-8     Document Type: Article

References (45)

1. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Prac 87:4-14
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197
3. Yki-Järvinen H (1994) Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 343:91-95
4. McAuley K, Mann J (2006) Nutritional determinants of insulin resistance. J Lipid Res 47:1668-1676
5. Henriksen EJ, Teachey MK, Lindborg KA, Diehl CJ, Beneze AN (2008) The high-fat-fed lean Zucker rat: a spontaneous isocaloric model of fat-induced insulin resistance associated with muscle GSK-3 overactivity. Am J Physiol Regul Integr Comp Physiol 294:1813-1821
6. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Schölmerich J, Bollheimer LC (2006) Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 36:485-501
7. Kirimer N, Baser KHC, Tumen G (1995) Carvacrol rich plants in Turkey. Chem Nat Comp 31:37-42
8. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244-251
9. Kallistratos G, Evangelou A, Agnantis N, Fasske E, Karkabounas S, Donos A (1994) Enhancement of the antineoplastic effect of anticarcinogens on benzo(a)pyrene-treated Wistar rats, in relation to their number and biological activity. Cancer Lett 82:153-165
10. Evangelou A, Kalpouzos G, Karkabounas S, Liasko R, Nonni A, Stefanou D, Kallistratos G (1997) Dose-related preventive and therapeutic effects of antioxidants-anticarcinogens on experimentally induced malignant tumors in Wistar rats. Cancer Lett 115:105-111
11. Hotta M, Nakata R, Katsukawa M, Hori K, Takahashi S, Inoue H (2010) Carvacrol, a component of thyme oil, activates PPAR and suppresses COX-2 expression. J Lipid Res 51:132-139
12. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471
13. Wang PR, Guo Q, Ippolito M, Wu M, Milot D, Ventre J, Doebber T, Wright SD, Chao YS (2001) High-fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. Eur J Pharmacol 427:285-293
14. Mudaliar S, Henry RR (2001) New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 52:239-257
15. Trinder P (1969) Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6:24
16. Drabkin DL, Austin JM (1932) Spectrophotometric constants for common haemoglobin derivatives in human, dog and rabbit blood. J Biol Chem 98:719-733
17. Nayak SS, Pattabiraman TN (1981) A new colorimetric method for the estimation of glycosylated hemoglobin. Clin Chim Acta 109:267-274
18. Burgi W, Briner M, Franken N, Kessler AC (1988) One-step sandwich enzyme immunoassay for insulin using monoclonal antibodies. Clin Biochem 21:311-314
19. Brandstrup N, Kirk JE, Bruni C (1957) The hexokinase and phosphoglucoisomerase activities of aortic and pulmonary artery tissue in individuals of various ages. J Gerontol 12:166-171
20. Koide H, Oda T (1959) Pathological occurrence of glucose-6-phosphatase in serum in liver diseases. Clin Chim Acta 4:554-561
21. Gancedo JM, Gancedo C (1971) Fructose-1,6-diphosphatase, phosphofructokinase and glucose-6-phosphate dehydrogenase from fermenting and non fermenting yeasts. Arch Microbiol 76:132-138
22. Bergmeyer HU, Bergmeyer IN (1984) Glucose 6-phosphate dehydrogenase. Methods of Enzymatic Analysis. Verlag Chemie, Weinheim, pp 222-223
23. Morales MA, Jabbay AJ, Tenenzi HP (1975) Mutation affecting accumulation of glycogen. Neurospora News let 20:24-25
24. Reitman S, Frankel S (1957) A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 28:56-63
25. Kind PR, King EJ (1954) Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. J Clin Pathol 7:322-326
26. Rosalki SB, Rau D (1972) Serum gamma-glutamyl transpeptidase activity in alcoholism. Clin Chim Acta 39:41-47
27. Ouwens DM, Boer C, Fodor M, de Galan P, Heine RJ, Maassen JA, Diamant M (2005) Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia 48:1229-1237
28. Zhang F, Ye C, Li G, Ding W, Zhou W, Zhu H, Chen G, Luo T, GuangMLiu Y, Zhang D, Zheng S, Yang J, Gu Y, Xie X, Luo M (2003) The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp Anim 52:401-407
29. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, Galloway JA, Frank BH, Karrison T, Van Cauter E (1988) Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Inves 81:435-441
30. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk(beta). Science 293:1673-1677
31. Kopelman PG (2000) Obesity as a medical problem. Nature 404:635-643
32. Kissebah AH, Peiris AN (1989) Biology of regional body fat distribution: relationship to non-insulin- dependent diabetes mellitus. Diabetes Metab Rev 5:83-109
33. Folli F, Saad MJ, Backer JM, Kahn CR (1992) Insulin stimulation of phosphatidylinositol 3-kinase activity and association with insulin receptor substrate 1 in liver and muscle of the intact rat. J Biol Chem 267:22171-22177
34. Lewis GF, Carpentier A, Adeli K, Giacca A (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23:201-229
35. Gabriely I, Barzilai N (2003) Surgical removal of visceral adipose tissue: effects on insulin action. Curr. Diab. Rep. 3:201-206
36. Cho S, Choi Y, Park S, Park T (2012) Carvacrol prevents diet-induced obesity by modulating gene expressions involved in adipogenesis and inflammation in mice fed with high-fat diet. J Nutr Biochem. 23:192-201
37. Alberti KG, Press CM (1982) The biochemistry and the complications of diabetes. In: Keen H, Jarrett J (eds) Complications of Diabetes. Edward Arnold, London, pp 231-270
38. Hikino H, Kobayashi M, Suzuki Y, Konno C (1989) Mechanisms of hypoglycemic activity of aconitan A, a glycan from Aconitum carmichaeli roots. J Ethnopharmacol 25:295-304
39. Kurosaki E, Nakano R, Momose K, Shimaya A, Suzuki T, Shibasaki M (2003) Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats. Eur J Pharmacol 468:151-158
40. Khan Proietto J, Song S, Andrikopoulos S, Filippis Anne W, Thorburn David (2001) Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin. Am J Physiol Endocrinol Metab 28:E275-E282
41. Baquer NZ, Gupta D, Rajo J (1998) Regulations of metabolic pathways in liver and kidney during experimental diabetes. Effect of antidiabetic compounds. Indian J Clin Biochem 13:63-80
42. Loria P, Lonardo A, Carulli L, Verrone AM, Ricchi M, Lombardini S, Rudilosso A, Ballestri S, Carulli N (2005) Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 22:31-36
43. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JG (1999) A prospective study the causes of notably raised aspartate transaminase of liver origin. Gut 45:129-133
44. Perry IJ, Wannamethee SG, Shaper AG (1998) Prospective study of serum gamma glutamyltransferase and risk of NIDDM. Diabetes Care 21:732-737
45. Aristatile B, Al-Numair KS, Veeramani C, Pugalendi KV (2009) Effect of CVL on hepatic marker enzymes and antioxidant status in D-galactosamine-induced hepatotoxicity in rats. Fundam Clin Pharmacol 23:757-765